These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 35349717)

  • 1. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia.
    Jiang H; Li L; Zhang X; He J; Chen C; Sun R; Chen Y; Xia L; Wen L; Chen Y; Liu J; Zhang L; Lv W
    J Cachexia Sarcopenia Muscle; 2024 Dec; 15(6):2417-2425. PubMed ID: 39254080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    Miao L; Miao T; Zhang Y; Hao J
    BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.
    Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
    Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
    Zhao SS; Yiu ZZN; Barton A; Bowes J
    JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.
    Baumeister SE; Holtfreter B; Reckelkamm SL; Kocher T; Alayash Z; Ehmke B; Baurecht H; Nolde M
    J Clin Periodontol; 2023 Jan; 50(1):114-120. PubMed ID: 36054135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis.
    Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L
    Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
    Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
    EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
    Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
    Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation.
    Liu C; Chu X; Biao Y; Jin Q; Zhang Y; Gao Y; Feng S; Ma J; Zhang Y
    Lipids Health Dis; 2024 Oct; 23(1):327. PubMed ID: 39358768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
    Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
    Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.
    Zhao R; Wang W; Zhang W; Lu J; Liu Y; Guo J; Yang L; Zhang Z; He C; Gu X; Wang B
    Sci Rep; 2024 Jul; 14(1):16885. PubMed ID: 39043809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
    Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.